Subscribe to Newsletter
Subspecialties Retina

Aflibercept in Europe: Setting New Standards in Retinal Disease Care

Strength and durability in the real world

Subspecialties Retina

Light Years Ahead

| Roisin McGuigan

What if there was an imaging technique that could detect retinal disease processes before any structural damage had even occurred?

Subspecialties Basic & Translational Research

AMD Clinical Trials

| Mark Hillen, Roisin McGuigan

AMD is the leading cause of blindness in developed countries, and the third-leading cause in developing countries.

Subspecialties Retina

Interleukin Forward to a Promising Future in AMD

| Mark Hillen

A novel signaling pathway that leads to choroidal neovascularization has been identified – with obvious therapeutic potential

Subspecialties Retina

First, Do No Harm

| Mark Hillen

A new study concludes that most surgical procedures used to treat optic disc pits are of no benefit – and may even be harmfu

Subspecialties Retina

The Poor Man’s Aflibercept?

| Michael Schubert

Like bevacizumab before it, ophthalmologists are trying off-label ziv-aflibercept (formulated for systemic use) in the eye. Masterstroke or madness?

Subspecialties Retina

From Intestine to Eye

| Michael Schubert

Gut microbes may be responsible for activating the T-cells that cause autoimmune uveitis

Subspecialties Retina

New Kid on the Block

| Michael Schubert

Can amniotic stem cells suppress pathologic retinal neovascularization?

Subspecialties Basic & Translational Research

Exploring Ophthalmology’s Orchard

| Mark Hillen

Across medicine, far fewer clinical trials report positive results these days. Whether the demise of sharp scientific practices or the lack of low-hanging fruit – does it apply to ophthalmology?

Subspecialties Retina

Analyzing the AMD Proteome

| Michael Koss

Looking at vitreous samples allows us to determine which proteins are involved in the disease process, and to what degree

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: